Pseudomonas and Cystic Fibrosis Request More Information Trial Objective This trial aims to learn if an investigational medication, called AR-501, is a safe and effective treatment for adults with CF who have Pseudomonas infection. Researchers are hoping AR-501 will stop the growth and spread of bacteria because of the anti-infective properties and different mechanisms of action compared to other antibiotics. The medication is given through a nebulizer, and participants will be randomly assigned to receive the investigational medication or the placebo. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate Adults with cystic fibrosis who consistently have Pseudomonas infection. Age: 18+ Gender: Any Gender Estimated Time Commitment 10 visits over 2 months Visits vary in length with the longest ones taking 3 hours. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Samantha Johnson 303.270.2598 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Aridis Pharmaceuticals Principal Investigators Jane Gross, MD, PhD + × Jane Gross, MD, PhD Associate Professor Division of Pediatric Pulmonary Medicine Division of Pulmonary, Critical Care & Sleep Medicine Department of Pediatrics Department of Medicine View Full Profile Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective This trial aims to learn if an investigational medication, called AR-501, is a safe and effective treatment for adults with CF who have Pseudomonas infection. Researchers are hoping AR-501 will stop the growth and spread of bacteria because of the anti-infective properties and different mechanisms of action compared to other antibiotics. The medication is given through a nebulizer, and participants will be randomly assigned to receive the investigational medication or the placebo.